When conducting stock research, investors may want to take a look at what the covering analysts are saying about the company. Zacks Research provides an average broker rating which is compiled using polled sell-side analysts. After a recent scan, we can see that the current ABR for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) is 1.17. Research firms may use various terminologies to describe their stock recommendations. This particular rating falls on a numerical scale from 1 to 5. A 1 rating would point to a Strong Buy, and a score of 5 would indicate a Strong Sell rating. The average broker rating helps investors by offering a general feel for sell-side sentiment on company shares. We have also noted that 6 analysts currently have the stock rated as a Buy or Strong Buy.
Investors will most likely make plenty of mistakes when dealing with the equity market. Learning from these mistakes is what will propel the individual forward. Those who don’t learn from their mistakes are destined to repeat, and failure might be right around the corner. Every investor strives to spot that uncovered stock before it explodes. However, chasing returns from big winners that have already made their moves may end up leaving the investor befuddled. Even though a stock has been hot, there is no guarantee that it will stay hot. Many investors may get stock tips from friends or colleagues. Of course the tips may be legitimate, but they could just be irrelevant. When it comes to stock picking strategies, investors might be best served to make sure that they have done the actual research themselves. Making trades based on tips or rumors may place the investor in a tough spot for future market success.
Viewing some popular support and resistance marks on shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX), we can see that the 52-week high is presently $59.45, and the 52-week low is currently $24.93. When the stock is trading near the 52-week high or 52-week low, investors may be on the lookout for a potential break through the level. Looking at recent action, we can see that the stock has been trading near the $24.93 level. Investors may also want to track historical price activity. Over the past 12 weeks, the stock has changed -31.79%. Looking further back to the beginning of the calendar year, we note that shares have moved -50.25%. Over the previous 4 weeks, shares have seen a change of -43.03%. Over the last 5 trading sessions, the stock has moved -6%. Investors will be monitoring stock activity over the next few days to try and gauge which way the momentum is shifting.
Wall Street analysts tracking shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) have been closely monitor company activities and fundamentals. They often create research reports to assist with investment decisions. On a consensus basis, analysts have set a target price of $57.7 on the stock. This number may be different from the First Call consensus target estimate. Analysts that routinely cover the company may use different techniques in order to create a future target price. Because of the different methods, price targets may differ greatly from one analyst to another.
Shifting gears, we can see that the current quarter EPS consensus estimate for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) is -1.29. This EPS estimate is using 4 sell-side analysts polled by Zacks Research. For the prior reporting period, the company posted a quarterly EPS of -1.54. As we move through earnings season, all eyes will be on the company to see if they can beat analyst estimates and show improvement from the last quarter. When a company reports actual earnings numbers, the surprise factor can cause a stock price to realize increased activity. Investors and analysts will be closely watching to see how the earnings results impact the stock after the next release. Many investors will decide to be cautious around earnings releases and delay buy/sell moves until after the stock price has steadied.